These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8052356)

  • 21. Membrane biocompatibility: clinical significance and therapeutic implications.
    Dumler F; Levin NW
    Int J Artif Organs; 1985 Sep; 8(5):257-62. PubMed ID: 3910591
    [No Abstract]   [Full Text] [Related]  

  • 22. Evaluation of a new polyamide membrane (Polyflux 130) in high-flux dialysis.
    Schaefer RM; Gilge U; Goehl H; Heidland A
    Blood Purif; 1990; 8(1):23-31. PubMed ID: 2198889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membrane selection for renal replacement therapy: a mountain or molehill?
    Farrell PC; Odell RA
    Contrib Nephrol; 1985; 44():97-111. PubMed ID: 3886286
    [No Abstract]   [Full Text] [Related]  

  • 24. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis.
    Küchle C; Fricke H; Held E; Schiffl H
    Am J Nephrol; 1996; 16(6):484-8. PubMed ID: 8955759
    [TBL] [Abstract][Full Text] [Related]  

  • 25. May colchicine therapy be of value in the prevention of dialysis amyloidosis?
    Arik N; Yüksel H; Adam B; Akpolat T; Ozdemir O
    Nephron; 1996; 73(2):365-6. PubMed ID: 8773394
    [No Abstract]   [Full Text] [Related]  

  • 26. Adsorption of beta 2-microglobulin on dialysis membranes: comparison of different dialyzers and effects of reuse procedures.
    Goldman M; Lagmiche M; Dhaene M; Amraoui Z; Thayse C; Vanherweghem JL
    Int J Artif Organs; 1989 Jun; 12(6):373-8. PubMed ID: 2674020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavior of beta 2-microglobulin (B2-m) serum levels in uremic patients.
    Mioli VA; Balestra E; Bibiano L; Dellabella S; Fanciulli E; Gaffi G; Perilli A; Petroselli F; Ricciatti AM; Carletti P
    Int J Artif Organs; 1994 Nov; 17(11):576-80. PubMed ID: 7744516
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hypoxemia during hemodialysis using acetate versus bicarbonate dialysate.
    Abu-Hamdan DK; Desai SG; Mahajan SK; Muller BF; Briggs WA; Lynne-Davies P; McDonald FD
    Am J Nephrol; 1984; 4(4):248-53. PubMed ID: 6433711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radiolucent bone cysts and the type of dialysis membrane used in patients undergoing long-term hemodialysis.
    Miura Y; Ishiyama T; Inomata A; Takeda T; Senma S; Okuyama K; Suzuki Y
    Nephron; 1992; 60(3):268-73. PubMed ID: 1565178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of lupus anticoagulant and anticardiolipin antibodies in haemodialysis patients.
    Phillips AO; Jones HW; Hambley H; Hillis AN; Hendry BM
    Nephron; 1993; 65(3):350-3. PubMed ID: 8289982
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of dialyzer membrane on interleukin-1beta (IL-1beta) and IL-1beta-converting enzyme in mononuclear cells.
    Linnenweber S; Lonnemann G
    Kidney Int Suppl; 2001 Feb; 78():S282-5. PubMed ID: 11169027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Artificial kidney: status of the art and new perspectives.
    Stefoni S; Cianciolo G; Colì L; Raimondi C; Dalmastri V; Donati G; Manna C; Grammatico F
    Artif Cells Blood Substit Immobil Biotechnol; 2003 May; 31(2):111-2. PubMed ID: 12751828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Amyloidosis in patients under hemodialysis. Therapeutic strategy].
    Dueymes JM; Vernier I
    Presse Med; 1987 Jun; 16(25):1245-6. PubMed ID: 2955382
    [No Abstract]   [Full Text] [Related]  

  • 34. Animal models to study the cardiopulmonary effects of artificial kidney membranes.
    Cheung AK
    Blood Purif; 1987; 5(2-3):155-61. PubMed ID: 3113447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of dialysate buffer on serum beta-2-microglobulin levels in chronic hemodialysis.
    Küchle C; Lang SM; Schiffl H
    Nephron; 1998; 79(1):99-100. PubMed ID: 9609469
    [No Abstract]   [Full Text] [Related]  

  • 36. Amyloidosis and its relationship to different dialysers.
    van Ypersele de Strihou C; Floege J; Jadoul M; Koch KM
    Nephrol Dial Transplant; 1994; 9 Suppl 2():156-61. PubMed ID: 8065608
    [No Abstract]   [Full Text] [Related]  

  • 37. Heparin free hemodialysis using heparin coated hemophan.
    Mujais SK; Chimeh H
    ASAIO J; 1996; 42(5):M538-41. PubMed ID: 8944937
    [No Abstract]   [Full Text] [Related]  

  • 38. [Removal of beta 2-microglobulin].
    Gejyo F; Hasegawa S; Homma N; Okada M; Maruyama S; Arakawa M
    Nihon Rinsho; 1991 Dec; 49 Suppl():601-5. PubMed ID: 1808323
    [No Abstract]   [Full Text] [Related]  

  • 39. Granulocyte-monocyte colony-stimulating factor levels during hemodialysis-induced leukopenia.
    Kolb G; Klausmann M; Eckle I; Müller T; Lange H; Havemann K
    Nephron; 1993; 65(3):466-8. PubMed ID: 8290002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Countermeasure for patients with amyloidosis due to hemodialysis].
    Gejo F
    Nihon Naika Gakkai Zasshi; 1995 Oct; 84(10):1673-7. PubMed ID: 8537723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.